Case Study

Pediatric Sinonasal Rhabdomyosarcoma: Clinical Characteristics and Surgical Role

Ali Al Momen1*, Saad M. Alshammari2, Abdullah A Al Shakh3, Aziza A Alzubaidi4, Ahoud Almuneef5, Mohammed A. Alfaalh6 and Saad S Alotaibi3

1Consultant Rhinology & Skull Base Surgery, King Fahad Specialist Hospital, Kingdom of Saudi Arabia
2ENT Specialist, Imam Abdulrahman bin Faisal University, Eastern Region, Kingdom of Saudi Arabia
3Medical Intern, Saudi Program, Kingdom of Saudi Arabia
4Pediatric Senior Resident, Saudi Program, Kingdom of Saudi Arabia

© 2020 Ali Al Momen. Hosting by Science Repository. All rights reserved

ARTICLE INFO

Article history:
Received: 2 March, 2020
Accepted: 18 March, 2020
Published: 20 March, 2020

Keywords:
Rhabdomyosarcoma
pediatrics
sinonasal
paranasal sinuses

ABSTRACT

Introduction: Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma. It represents 5-8% of pediatric tumors. Head and neck is considered the most common site of RMS origin (40%). Parameningeal, orbital and non parameningeal RMS approximately represent 50%, 25% and 25% respectively. Histopathological evaluation demonstrates small round cells with high cytological variability which stain positive with desmin, myogenin and MyoD1. The mainstay treatment of RMS depends on chemotherapy and radiation therapy with a limited role of surgery.

Method: A retrospective chart review for pediatric sinonasal rhabdomyosarcoma diagnosed and managed at King Fahad Specialist Hospital, Dammam, Saudi Arabia, and a literature review of pediatric sinonasal rhabdomyosarcoma was conducted.

Results: A total of four cases were identified for the period (2011-2017), and a thorough review of their medical records and radiological imaging were done.

Conclusion: Pediatric sinonasal rhabdomyosarcoma may initially present with symptoms mimicking rhinosinusitis. Biopsy and histological evaluation are the most essential steps to exclude malignancy. Intergroup Rhabdomyosarcoma Studies (IRS) established a staging system based on tumor extension and resectability. The role of surgery in RMS may be limited for obtaining biopsies for diagnosis and for palliative purposes. Popular antineoplastic agents used to treat RMS include vincristine, cyclophosphamide, actinomycin D, and Adriamycin. Chemotherapy with alkylating agents has achieved a relapsed free survival 90% for nonparameningeal tumors and 65% for parameningeal tumors.

Introduction

Rhabdomyosarcoma is considered to be the most common soft tissue sarcoma among the pediatric population [1, 2]. It is a rare tumor, representing 5-8% of pediatric tumors [3]. RMS behaves as an aggressive malignant tumor and has a tendency of early metastasis [4]. Variable subtypes include embryonal, alveolar, botryoid variant, spindle cell embryonal and anaplastic, showed prognostic values [5]. Neviod basal cell carcinoma (Gorlin syndrome), Neurofibromatosis type 1, Beckwith-Wiedeman syndrome and Rubinstein-Taybi syndrome, p53 tumor suppressor gene mutations and rhabdomyosarcoma oncogene mutations have been associated with rhabdomyosarcoma [6-9]. Head and neck is considered the most common site of RMS origin (40%). Parameningeal, orbital and non parameningeal RMS approximately represent 50%, 25% and 25% respectively [10, 11]. The initial symptoms of pediatric sinonasal rhabdomyosarcoma may mimic rhinosinusitis and delay diagnosis. Comprehensive clinical evaluation with the detailed history and physical examination is crucial. The endoscopic and

*Correspondence to: Ali Al Momen, DConsultant Rhinology & Skull Base Surgery, King Fahad Specialist Hospital, Dammam, Kingdom of Saudi Arabia; E-mail: ali.moumen@kfsh.med.sa

© 2020 Ali Al Momen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository. All rights reserved.

http://dx.doi.org/10.31487/j.IJSCR.2020.01.08
radiological evaluation must be performed before obtaining a biopsy of a unilateral nasal mass. Embryonal and alveolar histological subtypes represent the majority of pediatric rhabdomyosarcoma [12]. The histopathological evaluation usually demonstrates small round cells with high cytological variability. Immunohistochemical staining helps to confirm the diagnosis. RMS stained positive with desmin, myogenin and MyoD1. Cytokeratin, S-100 and epithelial membrane antigen do not stain, are negative, and help to exclude the other differential diagnoses for RMS [13]. The mainstay treatment of RMS depends on chemotherapy and radiation therapy with the limited role of surgery [14]. In this article, we present a case series of pediatric rhabdomyosarcoma involving paranasal sinuses, in addition to the clinical approach and treatment.

Method

A retrospective chart review for pediatric sinonasal rhabdomyosarcoma diagnosed and managed at King Fahad Specialist Hospital, Dammam, Saudi Arabia, was conducted after IRB committee approval. A total of 4 cases were identified for the period (2010-2017), and a thorough review of their medical records and radiological imaging were done. A literature review of pediatric sinonasal rhabdomyosarcoma was conducted.

Results

Case 1

An eight-year-old boy presented to the rhinology clinic with a complaint of nasal obstruction, rhinorrhea, and headache. The patient’s symptoms progressed over a month before referral to our hospital. He developed right eye ptosis and double vision. Nasal endoscopy showed a fleshy mass in the right nasal cavity (Figure 1) involving right sphenoid sinus, posterior ethmoids obstructing right choana and nasopharynx. Computed tomography (CT) of the nose and paranasal sinuses demonstrated a right sided sphenoid and posterior ethmoids lesion (Figure 2), extending to the infratemporal area and nasopharynx with the area of dehiscent skull base at the sphenoid sinus roof.

Figure 1: Endoscopic view of right nasal cavity shows a huge fleshy mass, obstructing choana and nasopharynx.

Figure 2: CT scan of paranasal sinuses, showing right sided lesion involving posterior ethmoids and sphenoid with extension to infratemporal fossa and dehiscent skull base at roof of sphenoid.

Figure 3: MRI of paranasal sinuses showed a large soft tissue mass extend from greater wing of sphenoid to pterygoid plates.

Figure 4: MRI T1 with contrast showing enhanced lesion partially encases the cavernous portion of the right internal carotid artery.

Figure 5: PET/CT demonstrate intracranial extension to the right middle cranial fossa mainly through foramen ovale.

Magnetic Resonance images (MRI) of paranasal sinuses showed a large soft tissue mass involving the right side of the body of the greater wing of the sphenoid bone extending down to the right pterygoid plates and the right parapharyngeal area (Figure 3). The tumor was displacing the right lateral and medial pterygoid muscles, invading right sphenoid sinus and right posterior ethmoid air cells with scalloping of the posterior wall of maxillary antrum and extending to the nasopharynx. The tumor
partially encases the cavernous portion of the right internal carotid artery (Figure 4). It appears iso-intense on T1WI, slightly high on T2WI with evidence of multiple signal voids centrally, which represent vessels. It was homogeneously enhancing post IV contrast administration and showed restriction on diffusion weighted images. The tumor showed intracranial extension to the right middle cranial fossa mainly through foramen ovale, as shown on PET CT scan (Figure 5). The patient underwent a biopsy of sinonasal mass under general anesthesia.

Histopathological evaluation showed malignant round blue cells, which demonstrated strong positive staining with desmin and myo-D. Further immunohistochemical staining with Pan-CK, CD45 and CD99 were negative. Morphological and immunohistochemical studies supported the diagnosis of rhabdomyosarcoma. Pediatric oncology referral and staging workup were conducted. RMS stage 4 was confirmed, and the patient started radiation and chemotherapy protocol. The patient is disease free on remission for 24 months post treatment.

Case 3

A three-year-old boy, presented with left facial swelling and left eye proptosis of a few weeks, associated with irritability and difficulty in sleeping. Clinical examination showed left eye proptosis and left periorbital and facial swelling. Nasal flexible endoscopy showed a large purple mass in the left nasal cavity. Imaging CT and MRI showed a large soft tissue mass at the left orbital region, extending to the maxillary sinus, suprasellar region, middle cranial fossa and left masticator space involvement. The mass lesion showed intermediate signal intensity on T1, T2WI, and almost heterogeneous enhancement and appeared restricted on DWI. The patient underwent urgent endoscopic nasal examination under general anesthesia and biopsy from the left sinonasal mass. Pathology confirmed small round malignant cells representing embryonal rhabdomyosarcoma stage IV. The patient received six cycles of chemotherapy in the form of cisplatin and daunorubicin.

Case 4

A six-year-old boy had been complaining of left eye proptosis for a month prior to presentation. Physical examination showed a left bluish large nasal mass obstructing the nasal cavity. Ophthalmological evaluation confirmed the presence of visual loss in the left eye and intact vision in the right eye. Computed tomography of the nose and the paranasal sinuses revealed left nasopharyngeal soft tissue lesion extending superiorly through the inferior orbital fissure into the posterior aspect of the orbit as well as into the anterior aspect of the left cavernous sinus. Endoscopic sinus surgery and debulking of left sinonasal mass were performed. Intraoperative findings showed the origin of the lesion to arise from the left pterygopalatine and infratemporal fossae with a very rich vascular supply from the maxillary artery (Figure 8). Endoscopic medial maxilllectomy was performed to access the pterygopalatine fossa and to excise the tumor. Further histopathological analysis revealed small malignant cells, which stained positive with desmin, vimentin, myogenin and WT-1 (cytoplasmic) stains. Negative staining with S-100, synaptophysin, SD99, Pan-CK, and CD45 confirmed the diagnosis of embryonal rhabdomyosarcoma. The patient...
was referred to pediatric oncology service for staging workup and to start chemoradiation therapy protocols.

**Discussion**

Rhabdomyosarcoma is a rare neoplasm, although it is known to be the most common soft tissue sarcoma among the pediatric population [1, 2]. The term comes from the Greek words, rhabdo (rod shape), myo (muscle), and sarcoma (fleshy growth). This tumor, representing 5-8% of pediatric tumors, considered an aggressive malignant tumor originating from mesenchymal cells of striated muscle, show tendency of early metastasis [3, 4]. RMS was described first in 1854 by Weber. In 1946, Stout described a well-defined morphology of rhabdomyoblast [15]. Several histological subtypes were identified and showed prognostic values. Embryonal (55-60%), alveolar (20-30%), botryoid variant (6%), spindle cell embryonal (3%) and anaplastic (1%) [5]. RMS has been associated with Nevoid basal cell carcinoma (Gorlin syndrome), Neurofibromatosis type 1, Beckwith-Wiedemann syndrome and Rubinstein-Taybi syndrome [6-9]. P53 tumor suppressor gene mutations and rhabdomyosarcoma oncogene mutations have been associated as well [16, 17].

**Table 1:** The role of surgery in RMS and Ewing’s sarcoma.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Surgical biopsy whenever possible</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
<td>To consider for palliative aims and urgent situations</td>
</tr>
<tr>
<td>Debulking surgery</td>
<td>Indicated in RMS when:</td>
</tr>
<tr>
<td>Radial surgery as primary treatment modality</td>
<td>• Complete tumor removal appears possible.</td>
</tr>
<tr>
<td></td>
<td>• It won’t lead to major functional and cosmetic consequences.</td>
</tr>
<tr>
<td></td>
<td>• In absence of high-risk features of meningeal involvement.</td>
</tr>
<tr>
<td>Surgery after primary chemoradiation</td>
<td>Not indicated in ES</td>
</tr>
<tr>
<td>Surgery after primary chemoradiation</td>
<td>Indicated in RMS when clinical and radiological re-staging reveals a resectable residual tumor (feasibility criteria are the same for primary resection).</td>
</tr>
<tr>
<td>Surgery after chemoradiation</td>
<td>Surgery after chemotherapy represents the current standard of cure for ES.</td>
</tr>
<tr>
<td>Contraindicated when an unacceptable degree of mutilations is expected.</td>
<td></td>
</tr>
<tr>
<td>Neck dissection</td>
<td>Recommended in alveolar subtype RMS when radical surgery on primary tumor is planned.</td>
</tr>
<tr>
<td>Not indicated in ES</td>
<td>In RMS the evidence for its efficacy is very limited.</td>
</tr>
<tr>
<td>Salvage surgery after locoregional relapse</td>
<td>Late relapses of ES successfully treated with resection are reported.</td>
</tr>
<tr>
<td>Metastasectomy</td>
<td>To consider for single, limited pulmonary metastasis.</td>
</tr>
</tbody>
</table>

Head and neck has been reported as the most common site of RMS origin (40%). The parameningeal, orbital and non parameningeal RMS approximately represent 50%, 25% and 25% respectively [10, 11]. Parameningeal sites of RMS usually involve the nasopharynx, nasal cavity, paranasal sinuses, middle ear and pterygopalatine fossa. As for the non parameningeal sites, parotid, oral cavity, oropharynx and larynx have been reported in the literature [18]. Orbital and superficial head and neck sites of RMS are considered as more favorable locations of disease compared to parameningeal sites [19, 20].

Pediatric sinonasal rhabdomyosarcoma may initially present with symptoms mimicking rhinosinusitis. Nasal obstruction, rhinorrhea, epistaxis, and headache might subsequently be manifested with further ocular and cranial symptoms [21]. Comprehensive clinical evaluation is crucial; a detailed clinical history and complete physical examination should be obtained. The endoscopic examination that shows a unilateral nasal mass necessitates radiological evaluation with computed tomography, and MRI if indicated, to exclude any vascular lesion or meningioencephalocele. Biopsy and histological evaluation is the most essential step to exclude malignancy, and it can be performed as an office-based endoscopic biopsy or in the operative theater under general anesthesia for uncooperative patients [22].

The majority of pediatric rhabdomyosarcoma demonstrate embryonal and alveolar histological subtypes. The embryonal RMS has been associated with loss of homozygosity on chromosome 11p15 [12]. The alveolar RMS demonstrates a chromosomal translocation [t(2;13)(q35;q14)] which lead to PAX3 gene and FKHR gene fusion and eventually tumor formation [23]. RMS histological examination usually demonstrates small round cells with high cytological variability. Immunohistochemical staining is utilized to confirm the histopathological diagnosis. RMS stained positive with desmin, myogenin and MyoD1. Negative staining with cytokeratin, S-100 and epithelial membrane antigen helps to exclude the other differential diagnoses for RMS [13]. Variable strength of staining to myogenin have been demonstrated between alveolar RMS (strong staining) and embryonal RMS (weak staining) [13, 24].

Intergroup Rhabdomyosarcoma Studies (IRS) established a staging system based on tumor extension and resectability. IRS trials showed improvement in survival with complete tumor resection; however, due to major morbidity after such extensive surgeries and with the development of chemotherapy and radiation therapy, surgical excision is less likely to be done [25-27]. Gatta G et al.’s review of rhabdomyosarcoma results in approximately 67% 5-years survival with multimodality therapy [28]. Rhabdomyosarcoma event-free survival (EFS) been reported lately were incentive [29, 30]. Ma X, et al. retrospective multicenter study in 10 years EFS of 53.4 ± 5.1% [31]. Singapore rhabdomyosarcoma experience reported by Aung L et al. optimistically reported 5-years EFS: of 75% [32].

The role of surgery in RMS may be limited for obtaining biopsies or for palliative purposes [14]. A few cases of nonparameningeal and non-orbital can be resected without major morbidities, in contrast to parameningeal tumors [33]. Only a few studies focused on the effectiveness and application of surgical resection [22]. P. Gradoni et al. reviewed and highlighted the role of surgery in children with head and neck rhabdomyosarcoma and Ewing’s sarcoma. Excluding orbital RMS, the review explained the surgical role including biopsy, debulking surgery, radical surgery as primary treatment modality, surgery after primary chemoradiation, neck dissection, salvage surgery after locoregional relapse and metastasectomy (Table 1) [34].

Popular antineoplastic agents used to treat RMS include vincristine, cyclophosphamide, actinomycin D, and Adriamycin [25-27]. These agents helped to improve the cure rate from 25% to 75% during the past 40 years. Unfortunately, parameningeal RMS is difficult to treat; reports showed more than forty percent of cases relapsed. Chemotherapy with alkylating agents have achieved a relapsed free survival 90% for nonparameningeal tumors and 65% for parameningeal tumors [35].

**Conclusion**

Pediatric sinonasal malignancies, including rhabdomyosarcoma may initially present with symptoms similar to rhinosinusitis, causing a delay in proper referral, diagnosis and management. Careful inspection and comprehensive examination with nasal endoscopy is crucial. Rhabdomyosarcoma incorporative management consists of radiation therapy and chemotherapy. The surgeon has a major role in providing the specimen for histopathological diagnosis. This article highlights the nature of pediatric RMS and emphasizes the surgeon to have low threshold in evaluating pediatric sinonasal masses to avoid diagnosis and management delay in order to increase survival and cure rates. Surgical role in RMS may further be investigated in order to obtain standardized criteria for surgical interventions.

**Conflicts of Interest**

None.

**References**


29. Salmon M, Tamim H, Medlej F, El Ariss T, Saad F et al. (2012) Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon. Pediatr Hematol Oncol 29: 322-334. [Crossref]


32. Aung L, Soe TA, Chang KT, Quah TC (2014) Singapore rhabdomyosarcoma (RMS) experience: shall we change our practice. Ann Acad Med Singapore 43: 86-95. [Crossref]


35. Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ et al. (2000) Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 18: 2427-2434. [Crossref]